Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with a <em>TRK</em> fusion–positive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting.
David Hyman, MD
Larotrectinib (LOXO-101), the novel pan-TRK inhibitor, induced responses in 3 out of 4 patients with aTRKfusionpositive solid tumor, according to findings presented in a press conference June 3 at the 2017 ASCO Annual Meeting. This well-tolerated oral agent could be on its way to becoming a standard of care among adults and children with any advanced cancer with this mutation.
“You would be hard-pressed to find a targeted therapy even within a single disease context that has results like this,” said David Hyman, MD, chief of early drug development at Memorial Sloan Kettering Cancer Center, who reported the findings during the press conference.
Twelve percent of patients in the study had a complete response and 64% a partial response; of the latter, Hyman reported, “most were not just meeting criteria for partial response, but had very deep tumor regressions.”
Larotrectinib is currently the only selective pan-TRK inhibitor in clinical development, Hyman said. He added that the oral agent may become the first to be used in a truly tumor-agnostic manner, and that, “To our knowledge, it may be the first cancer therapy ever developed simultaneously in both adults and children.”
TRKfusions occur when one of the TRKgenes becomes abnormally connected to another gene. This fusion event causes the TRKgene to be turned on and the cancer to grow. It’s estimated that, annually, up to 5000 patients harbor TRKfusion mutations, but Hyman stressed that “this number may significantly underestimate its prevalence due to inadequate ascertainment by many of the existing profiling technologies.”
ASCO reported thatTRKfusions were first discovered in colon cancer in 1982, but only recently has next-generation sequencing enabled them to be systematically detected. To date, more than 50 different partner genes that fuse with 1 of 3TRKgenes (NTRK 1, 2, and 3) have been identified.
Hyman explained thatTRKfusions typically follow 2 patterns: In adults, they occur rarely in more common cancers, such as brain, lung, colon, pancreatic, sarcoma, and melanoma; or, they occur more frequently in rare cancers, such as salivary and secretory breast cancer. This pattern also prevails in the pediatric setting, where the mutation is rarely seen in glioma and sarcoma, but more frequently in infantile fibrosarcoma and congenital nephroma, for example.
Although relatively rare, Hyman said that it is hard to find a tumor type where TRK fusions have not been reported. “One of the defining features ofTRKfusions is that they are not just found in one cancer type, but can be found in dozens of different cancer typesand in both children and adults.”
The study he reported at ASCO involved 55TRKfusionpositive adult and pediatric patients with advanced solid tumors representing 17 unique cancer types, who were enrolled in 1 of 3 clinical phase I/II clinical trials. Hyman emphasized that the patients were identified on the basis of local testing, and thus provide an example of “real world” experience: “We did not perform central screening to find the TRKfusions; in fact, 15 different laboratories identified the 55 patients who are described in this study.”
Hyman reported overall response rates (ORR) based on investigator assessment for 50 patients for whom confirmatory response data were available; larotrectinib (100 mg) was taken twice daily. The ORR was 76% (95% CI, 62%-87%), and this includes a partial response in 64% of patients and a complete response in 12%. Five additional patients, who joined the study too early to have had their confirmatory scans, all had at least a partial response to larotrectinib, Hyman noted.
Among the patients with a partial response to larotrectinib, Hyman said that two had such deep tumor regressions that they were actually able to be downstaged and taken forward to potentially curative surgery with pathologic complete responses.
No trend toward better results was seen with larotrectinib in one tumor type versus another. Responses occurred a median of 1.8 months into therapy, which Hyman explained was actually just a reflection of when the patients had their first scan: “In the clinic, patients reported dramatic improvement in their symptoms within days of beginning therapy.”
Larotrectinib is notable not only for its tumor- and age-agnostic paradigm, but also for its favorable toxicity profile, said Hyman. The most common side effects were fatigue and mild dizziness.
“This is an extremely well-tolerated therapy, with only 13% of patients requiring any form of dose modification and not a single patient discontinuing due to adverse events,” he said.
In concluding his presentation, Hyman noted that 93% of responding patients and 75% of all patients have remained on therapy or undergone surgery with curative intent. “I believe these data support larotrectinib as a new standard of care for these patients,” he said. However, for its potential to be fully realized, this will require that patients be tested more universally for the presence of this mutation, as well as for other tumor-agnostic biomarkers such as microsatellite instability. “To really enjoy these benefits,” Hyman said, “we’ll have to change the paradigm by which we test these patients.”
Larotrectinib is being developed by Loxo Oncology, Inc. Hyman reported that the company anticipates submitting a new drug application for the novel agent in late 2017 or early 2018.
Hyman DM, Laetsch TW, Kummar S, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.J Clin Oncol.2017;35 (suppl; abstr LBA2501).